These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 39612251)
1. Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States. Ailawadhi S; Cheng M; DerSarkissian M; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Cherepanov D J Manag Care Spec Pharm; 2024 Dec; 30(12):1431-1441. PubMed ID: 39612251 [TBL] [Abstract][Full Text] [Related]
2. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States. Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124 [No Abstract] [Full Text] [Related]
3. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
4. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences. Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159 [TBL] [Abstract][Full Text] [Related]
5. Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison. Anwer F; Lan T; Dolph M; Moradian H; Slaff S; Shih YH; Tang D Future Oncol; 2024 Nov; ():1-10. PubMed ID: 39611661 [TBL] [Abstract][Full Text] [Related]
6. Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes. Petrucci MT; Bringhen S; Entrala Cerezo C; Mendes J; Armeni P Hematology; 2024 Dec; 29(1):2432815. PubMed ID: 39611731 [TBL] [Abstract][Full Text] [Related]
7. Tobacco Product Use and Associated Factors Among Middle and High School Students - National Youth Tobacco Survey, United States, 2021. Gentzke AS; Wang TW; Cornelius M; Park-Lee E; Ren C; Sawdey MD; Cullen KA; Loretan C; Jamal A; Homa DM MMWR Surveill Summ; 2022 Mar; 71(5):1-29. PubMed ID: 35271557 [TBL] [Abstract][Full Text] [Related]
8. A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma. Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; van de Donk NWCJ; Katodritou E; Schjesvold F; Balari AS; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; Lonergan S; Ahmadi T; Liu Y; Wang J; Vieyra D; van Brummelen EMJ; Vanquickelberghe V; Sitthi-Amorn A; de Boer CJ; Carson R; Rodriguez-Otero P; Bladé J; Moreau P Future Oncol; 2024; 20(38):3043-3063. PubMed ID: 39287147 [TBL] [Abstract][Full Text] [Related]
9. Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors. Mease PJ; Ferrante SA; Shiff NJ; Fitzgerald TP; Chakravarty SD; Walsh JA Adv Ther; 2024 Dec; ():. PubMed ID: 39621228 [TBL] [Abstract][Full Text] [Related]
10. What Are the Functional, Radiographic, and Survivorship Outcomes of a Modified Cup-cage Technique for Pelvic Discontinuity? Mu W; Xu B; Wahafu T; Wang F; Guo W; Zou C; Cao L Clin Orthop Relat Res; 2024 Dec; 482(12):2149-2160. PubMed ID: 38991223 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM). Batinić J; Dreta B; Rinčić G; Mrdeža A; Jakobac KM; Krišto DR; Vujčić M; Piršić M; Jonjić Ž; Periša V; Sinčić Petričević J; Coha B; Holik H; Valković T; Stanić M; Krečak I; Stojanović A; Sajfert D; Bašić-Kinda S Medicina (Kaunas); 2024 Nov; 60(11):. PubMed ID: 39597090 [No Abstract] [Full Text] [Related]
12. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model. Harnan S; Kearns B; Scope A; Schmitt L; Jankovic D; Hamilton J; Srivastava T; Hill H; Ku CC; Ren S; Rothery C; Bojke L; Sculpher M; Woods B Health Technol Assess; 2024 Oct; 28(73):1-230. PubMed ID: 39487661 [TBL] [Abstract][Full Text] [Related]
13. Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results. Wing K; Williamson E; Carpenter JR; Wise L; Schneeweiss S; Smeeth L; Quint JK; Douglas I Health Technol Assess; 2021 Aug; 25(51):1-70. PubMed ID: 34463610 [TBL] [Abstract][Full Text] [Related]
14. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602 [TBL] [Abstract][Full Text] [Related]
15. Experiencing chronic cough symptoms for 3 years is associated with increased rates of healthcare resource use and higher healthcare costs in the United States compared to resolved chronic cough. Ke X; Ding H; Sun Y; Goto D; Waghmare P; Li M Curr Med Res Opin; 2024 Nov; ():1-23. PubMed ID: 39606816 [TBL] [Abstract][Full Text] [Related]
16. A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant. LeBlanc R; Thiant S; Terra R; Ahmad I; Claveau JS; Bambace N; Bernard L; Cohen S; Delisle JS; Lachance S; Kiss T; Roy DC; Sauvageau G; Roy J Curr Oncol; 2024 Nov; 31(11):7258-7274. PubMed ID: 39590165 [TBL] [Abstract][Full Text] [Related]
18. Qualitative evidence synthesis informing our understanding of people's perceptions and experiences of targeted digital communication. Ryan R; Hill S Cochrane Database Syst Rev; 2019 Oct; 10(10):ED000141. PubMed ID: 31643081 [TBL] [Abstract][Full Text] [Related]
19. Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis. Shabaninejad H; Kenny RP; Robinson T; Stoniute A; O'Keefe H; Still M; Thornton C; Pearson F; Beyer F; Meader N Health Technol Assess; 2024 Oct; 28(75):1-75. PubMed ID: 39487741 [TBL] [Abstract][Full Text] [Related]
20. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT. Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]